Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DV8F9L
|
|||
| Drug Name |
Epeleuton
|
|||
| Synonyms |
Epeleuton; Epeleuton [INN]; 1667760-39-5; FA9BPX1T6V; (S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; UNII-FA9BPX1T6V; 15(S)-HEPE-EE; CHEMBL5095178; AKOS040748327; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Hypertriglyceridemia [ICD-11: 5C80.1; ICD-10: E78.1, E78.3; ICD-9: 272.1, 427] | Phase 2 | [1] | |
| Non-alcoholic fatty liver disease [ICD-11: DB92; ICD-10: K76.0; ICD-9: 571.8] | Phase 2 | [2] | ||
| Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 2 | [3] | ||
| Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 2 | [1] | ||
| Company |
Afimmune
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H34O3
|
|||
| Canonical SMILES |
CCC=CCC(C=CC=CCC=CCC=CCCCC(=O)OCC)O
|
|||
| InChI |
InChI=1S/C22H34O3/c1-3-5-15-18-21(23)19-16-13-11-9-7-6-8-10-12-14-17-20-22(24)25-4-2/h5-7,10-13,15-16,19,21,23H,3-4,8-9,14,17-18,20H2,1-2H3/b7-6-,12-10-,13-11-,15-5-,19-16+/t21-/m0/s1
|
|||
| InChIKey |
DJYKWMOPVZGTRJ-PILRRHKESA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04365400) A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02941549) A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients. U.S.National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT05861453) An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.